UTILITY Therapeutics Ltd., is a biotechnology company focused on the U.S. development and commercialization of two European-approved antibiotics for the treatment of urinary tract infections (UTI), to address the significant threat faced by healthcare systems and patients from multi-drug resistant bacterial infections.

Biotechnology

UTILITY Therapeutics

UTILITY Therapeutics' headquarters in Ely, United Kingdom

Anita Das

Claus Maxel Henriksen

Anne Santerre Henriksen

Nina Aabenhus Kromann

Morten Sommer

Anders Kronborg

John Krayacich

The Advisors and Directors team at UTILITY Therapeutics provides strategic guidance, oversight, and expert advice to drive the U.S. development and commercialization of European-approved antibiotics for urinary tract infections. This team leverages their diverse expertise to address the challenges posed by multi-drug resistant bacterial infections, ensuring the company effectively navigates the healthcare landscape and achieves its mission.

Advisors and Directors

The Leadership Team at UTILITY Therapeutics is responsible for guiding the strategic direction and operational execution of the company’s mission to develop and commercialize innovative antibiotics for urinary tract infections. They collaborate on key initiatives related to research and development, regulatory compliance, and market strategy, leveraging their extensive expertise to navigate the complexities of the biotechnology landscape and drive the company’s growth and impact in combating multi-drug resistant infections.

UTILITY Therapeutics

Org chart

Board & advisors

Teams

Advisors and Directors

Leadership Team

Offices

UTILITY Therapeutics

Org chart

Board & advisors

Teams

Advisors and Directors

Leadership Team

Offices

Related companies